EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions

Zhimin Wu, Gaojian Lian, Lvheng He, Pingping Hu, Yujia Guo, Zehong Su

Immunology & Cell Biology · 2026

DOI: 10.1111/imcb.70078 ↗

At a glance

Übersichtsarbeit in Immunology & Cell Biology, 2026. Written by Zhimin Wu and 5 co-authors. Institution: Department of Biochemistry and Molecular Biology, Basic Medical College, University of South China, Hengyang, Hunan, China. Major MEDLINE topics: Autoimmune Diseases, STAT Transcription Factors, Signal Transduction, Janus Kinases. Cited 8 times so far (Crossref); 218 references. Funded by: Natural Science Foundation of Hunan Province, Key Grant of Research and Development in Hunan Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The Janus kinase (JAK)‐signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling cascade for the survival, activation, maturation, and differentiation of immune cells through interactions with cytokine receptors and transcription factors. Growing evidence indicates that autoimmune disorders are markedly affected by the JAK–STAT axis. Understanding the architecture and functions of the JAK–STAT axis has spurred the creation and authorization of a number of medications for managing autoimmune conditions in clinical settings. A mass of therapeutic agents (e.g., JAKinibs tofacitinib, baricitinib, STATinibs Stattic, FLLL32) and non‐coding RNA have been used in research in preclinical experiments or/and clinical trials and demonstrate significant potential for treating autoimmune diseases. Nevertheless, concerns about these medicines' long‐term safety and possible adverse consequences still exist. This narrative overview elaborates on the exact molecular underpinnings of the JAK–STAT axis, while also exploring the links among this pathway, adaptive immune cells, and autoimmune disorders. We also summarize the recently developed inhibitors of this pathway along with the present issues and future directions in the field.

Subjects

MeSH terms (MEDLINE)

Autoimmune DiseasesSTAT Transcription FactorsSignal TransductionJanus KinasesHumansAnimalsMolecular Targeted Therapy

Author keywords

Autoimmune diseasesJAK–STAT signaling pathwayimmune cellsinhibitors

Substances

STAT Transcription FactorsJanus Kinases

Authors and institutions

  • Department of Biochemistry and Molecular Biology, Basic Medical College, University of South China, Hengyang, Hunan, China.
  • Institute of Cytobiology and Genetic, Basic Medical College, University of South China, Hengyang, Hunan, China.

Funding

  • Natural Science Foundation of Hunan Province
  • Key Grant of Research and Development in Hunan Province

Cite

APA

Wu, Z., Lian, G., He, L., Hu, P., Guo, Y., & Su, Z. (2026). Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions. Immunology & Cell Biology. https://doi.org/10.1111/imcb.70078

Vancouver

Wu Z, Lian G, He L, Hu P, Guo Y, Su Z. Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions. Immunology & Cell Biology. 2026. doi:10.1111/imcb.70078

BibTeX
@article{Wu2026,
  author = {Wu, Zhimin and Lian, Gaojian and He, Lvheng and Hu, Pingping and Guo, Yujia and Su, Zehong},
  title = {Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions},
  journal = {Immunology & Cell Biology},
  year = {2026},
  doi = {10.1111/imcb.70078}
}
Start for free →